GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Asset Turnover

EYPT (EyePoint Pharmaceuticals) Asset Turnover : 0.03 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. EyePoint Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $10.52 Mil. EyePoint Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $312.58 Mil. Therefore, EyePoint Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. EyePoint Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2024 was -52.54%. It is also linked to ROA % through Du Pont Formula. EyePoint Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was -37.57%.


EyePoint Pharmaceuticals Asset Turnover Historical Data

The historical data trend for EyePoint Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Asset Turnover Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.42 0.21 0.19 0.17

EyePoint Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.05 0.03 0.03 0.03

Competitive Comparison of EyePoint Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Asset Turnover falls into.



EyePoint Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

EyePoint Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=46.018/( (180.356+355.184)/ 2 )
=46.018/267.77
=0.17

EyePoint Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=10.524/( (324.249+300.917)/ 2 )
=10.524/312.583
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


EyePoint Pharmaceuticals  (NAS:EYPT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

EyePoint Pharmaceuticals's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-117.444/223.5195
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-117.444 / 42.096)*(42.096 / 312.583)*(312.583/ 223.5195)
=Net Margin %*Asset Turnover*Equity Multiplier
=-278.99 %*0.1347*1.3985
=ROA %*Equity Multiplier
=-37.57 %*1.3985
=-52.54 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

EyePoint Pharmaceuticals's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-117.444/312.583
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-117.444 / 42.096)*(42.096 / 312.583)
=Net Margin %*Asset Turnover
=-278.99 %*0.1347
=-37.57 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


EyePoint Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Goran Ando director
Wendy F Dicicco director
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer director ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906